Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Advanta VXT and Flixene PMCF Registry

NCT07161583 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of the registry is to evaluate the long-term safety and performance of Advanta VXT and Flixene vascular grafts for repair or replacement of peripheral arteries. This registry is also intended to provide further data on the clinical usefulness of the Advanta VXT and Flixene vascular grafts.

Interventions

  • DEVICE Advanta VXT Vascular Graft
  • DEVICE Flixene Vascular Graft

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital — Boston

Brittany Region

  • CHU de Brest — Brest

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2025-09-25
Est. Completion 2026-10

Sponsor

Atrium Medical Corporation

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07161583

The ClinicalTrials.gov registry entry for NCT07161583 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atrium Medical Corporation, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions — of which Advanta VXT Vascular Graft is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07161583 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Massachusetts, Brittany Region. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07161583 about?

NCT07161583 is a clinical study titled "Advanta VXT and Flixene PMCF Registry". The purpose of the registry is to evaluate the long-term safety and performance of Advanta VXT and Flixene vascular grafts for repair or replacement of peripheral arteries. This registry is also intended to provide further data on the clinical usefulness of the Advanta VXT and Flixene vascular graft...

What is the current status of trial NCT07161583?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-09-25. Estimated completion is 2026-10.

What conditions does trial NCT07161583 study?

This clinical trial studies the following conditions: Peripheral Arterial Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07161583?

The interventions under investigation include: Advanta VXT Vascular Graft (DEVICE), Flixene Vascular Graft (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07161583?

This trial is sponsored by Atrium Medical Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07161583 being conducted?

This trial has 2 study locations across Massachusetts, Brittany Region. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial